The collaboration is a non-financial partnership with a non-profit; no revenue or volume commitments are stated. Monitor future Tempus filings for any revenue recognition or expanded government contracts tied to this initiative.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $80.54entry
- T+1 · 6d ago −1.38%α −2.70% · $79.43
- T+4 · todayOpen
- T+5 · in 6h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SOTERIA Precision Medicine Foundation announced a collaboration with Tempus to provide genomic sequencing and AI-enabled diagnostic support for precision oncology care to U.S. active-duty and veteran military populations. The partnership expands Tempus's platform into a new patient cohort but does not disclose any financial terms, revenue commitments, or volume guarantees.
Key Facts
- Collaboration with SOTERIA Precision Medicine Foundation, a non-profit, to deliver genomic profiling and AI diagnostics to military cancer patients
- No financial terms, contract value, or revenue commitments disclosed in the release
- Tempus's platform will support SOTERIA's Cancer Hunt initiative for active-duty and veteran populations
- Partnership is non-exclusive and no stated minimum volume or duration
Financial Impact
No financial terms disclosed; impact is strategic and reputational, not quantifiable from this release
Risk Factors
- No financial terms disclosed, market may view as immaterial without revenue or volume commitments
- Partnership with a non-profit may not generate near-term revenue for Tempus
- Execution risk in reaching and enrolling the target military patient population
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302933873 |
Track record
45 reports on TEM
8 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +53.09% at T+60 after the Jul 30, 2026 report. 17 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 3/10 Viewing Entry $80.54 Now $64.76 −19.59% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $76.05 Now $64.76 −14.85% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 3/10 Entry $70.43 Now $64.76 −8.05% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 1/10 Entry $77.80 Now $64.76 −16.76% settles Feb 1
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $78.48 Now $64.76 −17.48% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $77.84 Now $64.76 −16.80% settles Jan 27
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 27, 202620d ago 144 Neutral 3/10 Entry $76.61 Now $64.76 −15.47% settles Jan 26
- Oct 23, 202624d ago 8-K Bullish 6/10 Entry $67.62 Now $64.76 −4.22% settles Jan 21
- Oct 22, 202626d ago EFFECT Neutral 4/10 Entry $63.81 Now $64.76 +1.49% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers